M. Maclean

发表

The dynamics of change: cancer patients' preferences for information, involvement and support.

P. Butow, M. Tattersall, S. Dunn, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

A. Oza, S. Hotte, M. Maclean, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial

A. Oza, H. Hirte, S. Hotte, 2005 .

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

A. Oza, H. Hirte, L. Siu, 2008, Clinical Cancer Research.

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

A. Oza, L. Seymour, W. Miller, 2005, Investigational New Drugs.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

M. Carducci, L. Siu, A. Kalita, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

A. Oza, L. Seymour, L. Siu, 2006, Cancer Chemotherapy and Pharmacology.

Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital

G. Pond, A. Oza, L. Siu, 2006, BMC Cancer.

The impact of COVID-19 on systemic anticancer treatment delivery in Scotland

D. Cameron, P. Hall, R. Petty, 2021, British Journal of Cancer.

550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors

G. Pond, J. Dancey, L. Siu, 2006 .

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

A. Oza, L. Seymour, M. Moore, 2005, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.

K. Bélanger, L. Seymour, L. Siu, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors.

R. Sullivan, M. Carducci, L. Siu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

E. Eisenhauer, K. Gelmon, M. Moore, 2003, Investigational New Drugs.

Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.

G. Pond, A. Oza, D. Hedley, 2007, International journal of radiation oncology, biology, physics.

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

T. Mak, M. Tsao, B. Bandarchi-Chamkhaleh, 2010, Molecular Cancer Therapeutics.

The use of reverse transcription polymerase chain reaction to identify metastases in sentinel lymph nodes of patients with breast cancer

M. Maclean, 2007 .

Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors

G. Pond, J. Dancey, L. Siu, 2007, Clinical Cancer Research.

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-fluorouracil in Patients with Advanced Colorectal Cancer Cancer Therapy: Clinical

L. Seymour, D. Jonker, E. Chen, 2022 .

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours

E. Eisenhauer, L. Siu, W. Walsh, 2007, Investigational New Drugs.

The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial

G. Pond, L. Siu, M. Maclean, 2007, Supportive Care in Cancer.

A phase I study of the pan-Bcl2 family inhibitor GX15-070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas.

J. Marshall, L. Siu, J. Kuruvilla, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer

L. Seymour, D. Jonker, E. Chen, 2009, Clinical Cancer Research.

719 POSTER Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients (pts) with advanced colorectal cancer (CRC)

L. Seymour, D. Jonker, E. Chen, 2007 .